Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GRITSTONE BIO, INC.

(GRTS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone bio, Inc. Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

11/10/2021 | 07:00am EST

Gritstone bio, Inc. published positive preclinical data in non-human primate models from the CORAL next-generation COVID-19 vaccine program against SARS-CoV-2, the coronavirus that causes COVID-19 disease. In a non-human primate challenge study, immunization with a self-amplifying mRNA (SAM) vaccine protected rhesus macaques against SARS-CoV-2 infection as either a homologous prime-boost regimen (2 doses) or as a single boost following an optimized chimpanzee adenoviral (ChAd) vector prime. In the study, a SAM vaccine encoding a prefusion stabilized SARS-CoV-2 spike glycoprotein demonstrated potent cellular and humoral immune responses at low doses in mice and rhesus macaques. The homologous prime-boost vaccination regimen of SAM at 3, 10 and 30 ?g induced potent neutralizing antibody titers in rhesus macaques at all dose levels, with the 10?g dose generating geometric mean titers (GMT) 48-fold greater than the GMT of a panel of SARS-CoV-2 convalescent human sera, and comparable to that observed with a ChAd and SAM heterologous prime-boost regimen. Spike-specific T cell responses were observed in all dose groups. SAM vaccination provided protective efficacy against SARS-CoV-2 challenge as both a homologous prime-boost and as a boost following ChAd prime, demonstrating reduction of viral replication in both the upper and lower airways. Protection was most effective with a SAM prime-boost vaccination regimen at 10 and 30 ?g and with a ChAd/SAM heterologous prime-boost regimen. The Gritstone CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering a stabilized spike protein and highly conserved T cell antigens derived from other viral genes of SARS-CoV-2 within either a self-amplifying mRNA lipid nanoparticle or a ChAd. An ongoing Gritstone-sponsored Phase 1 trial is evaluating SAM as a boost and immunogenicity enhancer of AstraZeneca's first-generation COVID-19 vaccine AZD1222 (Vaxzevria) in healthy adults = 60 years in the UK. Preliminary data from this trial are expected in early 1Q22. A two-dose SAM regimen is also being evaluated in the ongoing clinical trial sponsored by the National Institute of Health (NIH) Division of Microbiology and Infectious Disease (DMID) (NCT04776317, GO-009, GO-012), and in the Coalition for Epidemic Preparedness Innovations (CEPI)-funded, Gritstone-sponsored clinical trial in South Africa expected to begin by year end 2021.


ę S&P Capital IQ 2021
All news about GRITSTONE BIO, INC.
01/13Gritstone Starts Enrollment in Phase 2/3 Trial of Colorectal Cancer Vaccine
MT
01/13Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualize..
AQ
01/13Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualize..
CI
01/10GRITSTONE BIO, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/06UNIVERSITY OF MANCHESTER : Early data for multivariant COVID-19 vaccine booster shows prom..
AQ
01/05GRITSTONE BIO : Announces Positive Clinical Results from First Cohort of a Phase 1 Study (..
PU
01/04GRITSTONE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/04Gritstone Reports Positive Data From Study of Second-Generation COVID-19 Vaccine; Share..
MT
01/04Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (COR..
AQ
01/04Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 ..
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 48,0 M - -
Net income 2021 -73,9 M - -
Net cash 2021 80,4 M - -
P/E ratio 2021 -5,79x
Yield 2021 -
Capitalization 425 M 425 M -
EV / Sales 2021 7,17x
EV / Sales 2022 16,2x
Nbr of Employees 188
Free-Float -
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,25 $
Average target price 19,67 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
RaphaŰl Rousseau Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-51.40%425
CSL LIMITED-5.06%95 466
WUXI BIOLOGICS (CAYMAN) INC.-2.54%49 958
SAMSUNG BIOLOGICS CO.,LTD.-8.53%47 262
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.26%35 151